Dr. Koppel recently received a nearly $1 million grant from the Alzheimer’s Foundation of America to expand research into developing new treatments to address the hallucinations, delusions and aggression that come with dementia. The five-year study will employ tau brain imaging to determine the specific regions of vulnerability to psychotic symptoms and aims to develop novel immune therapies directed at the pathology so that future clinical trials will be possible.
“Millions living with Alzheimer’s disease need more targeted, effective treatments, which requires a better understanding of the disease mechanisms,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes. “Dr. Koppel’s research into the mechanisms of AD psychosis offers timely insights and points the way to new paths to explore therapies.”
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
About the Feinstein Institutes
The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.
Back to HCB News
